The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
通常価格
¥1,210 JPY
通常価格
セール価格
¥1,210 JPY
単価
あたり
税込み。
受取状況を読み込めませんでした
This case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme's pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (CVR). Was a CVR the magical solution to bridging the valuation gap?
【書誌情報】
ページ数:16ページ
サイズ:A4
商品番号:HBSP-UV6870
発行日:2014/10/22
登録日:2015/2/5
![HBSP-UV6870.jpg](http://harvard.bookpark.ne.jp/cdn/shop/products/HBSP-UV6870.jpg?v=1663847873&width=1445)